Cyclosporine Inhalation Solution

DRUG3 trials

Sponsors

APT Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), Pari Pharma GmbH

Conditions

Bronchiolitis ObliteransBronchiolitis, ExudativeBronchiolitis, ProliferativeConstrictive BronchiolitisGraft vs Host DiseaseLung Transplant

Phase 2

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome

CompletedNCT01287078

National Heart, Lung, and Blood Institute (NHLBI)Bronchiolitis, Exudative, Bronchiolitis Obliterans, Bronchiolitis, Proliferative +2

Start: 2011-01-29End: 2018-08-08Updated: 2020-09-24

L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

TerminatedNCT01334892

Pari Pharma GmbHBronchiolitis Obliterans

Start: 2009-12-31End: 2014-12-31Updated: 2015-04-14

Unknown Phase

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

APT Pharmaceuticals, Inc.Lung Transplant

Updated: 2012-09-17

Related Papers

Impact of Lung Function Decline on Mortality in Lung Transplant Recipients: Long-Term Results From the L-CsA-i Study for the Prevention of Bronchiolitis Obliterans Syndrome

Frontiers in Medicine2022-06-024 citations